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ABSTRACT 19 
A new small-scale continuous-flow High-Temperature Short-Time (HTST) pasteurizer has been 20 
designed for treating human milk. The efficacy of the new HTST device was assessed on inoculated 21 
Listeria monocytogenes, Staphylococcus aureus and Chronobacter sakazakii, as well as on raw 22 
human milk bacteria. The milk biochemical quality after HTST pasteurization was assessed in 23 
comparison to a standard Holder pasteurization, by determining the secretory IgAs (sIgAs) content, 24 
the protein profile, lysozyme and the bile salt stimulated lipase (BSSL) activities. No pathogen or 25 
bacterial growth was detected after HTST pasteurization with the new instrument. Changes in the 26 
protein profile were observed in the milk pasteurized according to both processes. The sIgAs 27 
content and BSSL activity were significantly higher in the milk pasteurized with the new device 28 
than in the same milk treated by the standard Holder pasteurization. In conclusion, the new HTST 29 
apparatus: (i) can effectively pasteurize human milk with a better retention of sIgAs content and 30 
BSSL activity; (ii) comply to human milk banking safety requirements. 31 
 32 
Keywords: Donor milk; HTST; Bile Salt Stimulated Lipase; Challenge tests; Secretory IgAs. 33 
 34 
 35 
INDUSTRIAL RELEVANCE 36 
Currently, 206 active human milk banks are located in Europe (and 13 more are planned). The 37 
majority of the European banks still use Holder-based pasteurizers, which, despite efficacy in 38 
ensuring microbiological safety, are known to reduce/disrupt important nutritional and non-39 
nutritional biological factors. Although already widely established in food industry, the advantages 40 
of HTST technology were tested only at small laboratory scale for human milk. The device tested in 41 
the present research was specifically designed to provide human milk banks with the technology 42 
they need to ensure a safe and lower-impact pasteurization process, that is suitable for  processing 43 
different volumes of donations. The device can pasteurize up to 10 l of milk per hour, with a 44 
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minimum volume of 100 ml. The system is designed to be cleaned-in-place (CIP) after each 45 
pasteurization run and sanitized immediately prior to the next use, being thus more suitable for 46 
treating pools of milk from different donors than milk from single donations. Italian and EU patents 47 
have been filed for the device, within a partnership between public research institutions, 48 
stakeholders (Italian association of donor milk banks), and a private company in the sector of dairy 49 
processing equipment. The device has achieved a Technology Readiness Level (TRL) 6 (Prototype 50 
demonstration in a relevant environment). The cost of the new device will be comparable to that of 51 
a typical human milk Holder pasteurizer. 52 
 53 
 54 
Abbreviations: 55 
Bile Salt Stimulated Lipase (BSSL) 56 
Colon Forming Units (CFU)  57 
High-Temperature Short-Time (HTST) 58 
Holder pasteurization (HoP) 59 
Human milk (HM) 60 
Human Milk Bank (HMB) 61 
Inoculated human milk (IHM)  62 
Original human milk (OHM)  63 
Pasteurized human milk (PHM) 64 
Raw human milk (RHM) 65 
Secretory IgAs (sIgAs) 66 
Sterile human milk (SHM) 67 
Total Viable Bacteria Count (TVC) 68 
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1. INTRODUCTION  79 
Thermal treatments are commonly applied for food processing, because of their ability to kill 80 
pathogens and inactivate potentially detrimental enzymes, such as lipases and proteases. The Holder 81 
pasteurization (HoP) method (62.5 °C for 30 min) is currently the recommended pasteurization 82 
method for human milk banks (HMBs), as it ensures that the human milk (HM) is microbiologically 83 
safe (Arslanoglu et al., 2010). However, heat processing, particularly under severe conditions, may 84 
give rise to chemical and physical changes that can impair the organoleptic properties and reduce 85 
the content or bioavailability of some nutrients (Arslanoglu et al., 2013; Tully, Jones, & Tully, 86 
2001). HM has an elevated biological value, thanks to the casein-to-whey ratio, high essential 87 
amino acid concentration and immunological components, such as immunoglobulins, lysozyme, 88 
and lactoferrin, which convey relevant antimicrobial properties (Andreas, Kampmann, & Mehring 89 
Le-Doare, 2015; Giribaldi, et al. 2012). Thermal treatments may also cause the unfolding of milk 90 
fat globule membrane proteins and whey proteins, whose end products are typically associated with 91 
off-flavours (Contador, Delgado, García-Parra, Garrido, & Ramírez, 2015). The loss of some 92 
biologically active components, including immunological components, due to HoP, is a main limit 93 
to the spread of donor human milk (Moro & Arslanoglu, 2012; Tully et al., 2001). The 94 
maximization of the biological and nutritional quality of donor HM is considered a scientific and 95 
social priority: the ESPGHAN Committee on Nutrition has pointed out that “future research should 96 
focus on the improvement of milk processing in human milk banks, particularly of heat treatment” 97 
(Arslanoglu et al., 2013). 98 
In a previous study by our group (Baro et al., 2011), the HTST method (72 °C for 15 s) showed to 99 
better preserve, in comparison to HoP, the milk protein profile and some of the key active 100 
components of HM, with potential consequences on the availability of important nutritive 101 
compounds, such as fatty acids and available lysine. 102 
In previous studies concerning the application of HTST to HM, other non-commercial devices were 103 
used, usually at a laboratory scale. Some authors used laboratory equipment, mainly consisting of 104 
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stainless steel tubing systems submerged in thermostated water baths, through which HM was 105 
pumped (Dhar, Fichtali, Skura, Nakai, & Davidson, 1996; Goldsmith, Eitenmiller, Toledo, & 106 
Barnhart, 1983; Terpstra et al., 2007); others injected milk through a sterile water stream in a plate-107 
type industrial heat exchanger (Goldblum et al., 1984); some research studies were conducted by 108 
directly heating and rotating small aliquots of milk, to simulate the typical thin-layering of dairy 109 
industry HTST devices (Goeltz et al., 2009; Hamprecht et al., 2004). Several studies involved 110 
simply heating small aliquots (from 40 μL to 4 mL) of HM in a bulk process (Mayayo et al., 2014; 111 
Mayayo et al., 2016; Silvestre et al., 2006; Silvestre et al., 2008). Moreover, variable heating times 112 
(5-15 s) and temperatures (71-75 °C) were adopted. All the reported processes, with the exception 113 
of that of Goldblum et al. (1984), are substantially different from industrial HTST processes. 114 
However, the introduction of HTST into the HMB routine has not been possible to date, due to the 115 
lack of specific low-volume designed instrumentation. In most of studies concerning the HTST 116 
processing of HM, quantitative comparisons, with respect to standard pasteurization, have been 117 
described, but HoP was often simulated on small aliquots, rather than being performed according to 118 
real HMB-implemented protocols, thus representing a possible bias for the generalization of the 119 
comparison with novel technologies (Peila et al., 2015). 120 
When projecting, creating, testing and patenting a new type of low-volume HTST pasteurizer 121 
(Cavallarin et al., 2015), it was considered that: i) it was intended for HMBs, and thus consistency 122 
with guideline requirements was mandatory; ii) the dairy industry HTST standards (72 °C holding 123 
temperature for 15 s holding time) had to be fulfilled; iii) temperature control had to be ensured by 124 
means of adequate probes; iv) a comparison with the HoP process had to be made using the HMB 125 
implemented device. 126 
The present research is aimed at reporting the efficacy of a new, low-volume, continuous flow 127 
commercial HTST pasteurizer on HM quality in terms of: (i) bacterial inactivation, and (ii) 128 
preservation of the main immunological and nutritional components. 129 
 130 
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 131 
2. MATERIALS AND METHODS 132 
2.1 Preliminary tests 133 
In order to verify the pasteurization process, a preliminary experiment was run. A bovine milk 134 
sample was pasteurized and the alkaline phosphatase and peroxidase activities were determined in 135 
the treated sample. Alkaline phosphatase is a heat sensitive enzyme in milk that is used as indicator 136 
of pasteurization. If milk is properly pasteurized, alkaline phosphatase is inactivated. 137 
Lactoperoxidase is one of the most heat-stable enzymes found in milk and it is preserved after a 138 
correct HTST pasteurization. The raw bovine milk was purchased from a local automatic 139 
distributor, collected in a sterile Pyrex bottle, delivered refrigerated to the lab and stored 140 
refrigerated until it was processed. The milk (1 L) was divided into two aliquots: one was kept 141 
refrigerated until it was analysed; the other was subjected to HTST pasteurization by means of the 142 
new instrument (described in 2.3), collected in a sterile Pyrex bottle and stored refrigerated until the 143 
analysis. Alkaline phosphatase activity was tested by means of the enzymatic hydrolysis of p-144 
nitrophenol phosphate, which yields p-nitrophenol and inorganic phosphate (ISO/TS 6090, 2004). 145 
Peroxidase activity was determined by means of Storch’s peroxidase test, which measures the 146 
oxygen transfer from hydrogen peroxide to other readily oxidisable substances (Council Directive 147 
92/46/EEC).  148 
 149 
2.2 Sample collection and pooling of specimens 150 
The HM samples were obtained from the HMB of the Città della Scienza e della Salute in Torino, 151 
Italy, from eight healthy donor mothers. The donors cleaned their hands and breasts according to 152 
the HMB guidelines. The milk specimens were collected in sterile bisphenol-free polypropylene 153 
bottles (Flormed, Naples, Italy) using a breast pump and stored, by the HMB, at -20°C until 154 
processed.  155 
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The HM samples were pooled separately for the two experiments, which were referred to as 156 
Experiment 1 and Experiment 2. Panel A and panel B in Figure 1 show the experimental workflows 157 
for Experiment 1 and Experiment 2, respectively. 158 
In Experiment 1, frozen samples from individual HM donors were thawed overnight in a 159 
refrigerator, and then in tap water, and were pooled to achieve a final volume of about 2 L in a 160 
sterile Pyrex bottle. They were then mixed carefully, divided into 100 mL aliquots and placed in 161 
sterile bisphenol-free polypropylene bottles. One aliquot of original HM (OHM) was used directly 162 
to determine the HM background microflora. The remaining aliquots were pasteurized intensively 163 
in a water bath for 1 hour at 63 °C (prolonged Holder Pasteurization) to kill all of the existing 164 
vegetative forms of microorganisms (SHM). One aliquot was kept for about 20 h in the refrigerator, 165 
and then analysed to verify the absence of microbial contaminants. The other aliquots were 166 
immediately frozen and used later for inoculation (IHM) (section 2.4.3). 167 
In Experiment 2, samples from individual HM donors were obtained frozen from the HMB, thawed 168 
overnight in a refrigerator, and then in tap water, and were pooled to achieve a final volume of 169 
about 400 mL in a sterile Pyrex bottle. They were mixed carefully and divided into three sterile 170 
bisphenol-free polypropylene bottles. Two aliquots were subjected to standard HoP, in two separate 171 
trays, in the HMB facilitiesThe two samples were processed in the same batch and differed only for 172 
their position in the pasteurizer. One aliquot was subjected to HTST pasteurization using the new 173 
instrument. The Raw (RHM), Holder (HoP-HM) and HTST (HTST-HM) pasteurized samples were 174 
kept frozen at -20°C until analysis, with the exception of 10 mL per sample, which was kept 175 
refrigerated for about 20 h before being used for microbial screening.  176 
 177 
2.3 Pasteurization equipment 178 
HoP was performed in an HM pasteurizer (Metallarredinox, Zingonia-Verdellino (Bg), Italy) 179 
located in the HMB of the Città della Scienza e della Salute in Torino, Italy. A patent pending 180 
HTST- based proprietary system (Giada s.r.l, Villafranca Piemonte (To), Italy) (Cavallarin et al., 181 
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2015), specifically created for use in HMBs, was used for HM pasteurization at 72 °C for 15 s. The 182 
new instrument is a bench-top device that consists of a system of tubular heat exchangers, which are 183 
used for both heating and cooling. The thermostatic stay section has been designed to be isolated, 184 
and temperature monitoring is achieved by means of specific digital probes placed at critical control 185 
points. The new HTST pasteurizer was designed to meet the specific requirements of safety and 186 
efficacy of HMBs: an increase in milk temperature in a few seconds, a thermostatic stay of 15 s 187 
(max temperature drop of 1.5 °C during pasteurization) and fast cooling of the pasteurized milk (15 188 
s to achieve a lower temperature than 20 °C). 189 
 190 
2.4 Experiment 1- Challenge tests 191 
2.4.1 Microbiological profiling of the RHM and OHM background microflora. 192 
In order to assess the natural contamination of the milk, the OHM (Pool 1) and RHM (Pool 2) 193 
background microflora were determined in duplicate. This process included enumeration of the total 194 
aerobic mesophilic viable count (by Plate Count Agar (Merck, Darmstadt, Germany) – method 195 
EN/ISO 4833, 2006), Enterobacteriaceae (by Crystal-Violet Neutral-Red Bile Glucose Agar 196 
(Merck) - method AFNOR V08-054) and coagulase-positive Staphylococci (by Baird Parker RPF 197 
Agar (Biolife Italiana, Milan, Italy) – method EN/ISO 6888, 1999). The same microbiological tests 198 
were performed on SHM, to verify the efficacy of the prolonged Holder pasteurization before 199 
inoculation. 200 
 201 
2.4.2 Bacterial test strains and preparation of the cell suspensions. 202 
L. monocytogenes (ATCC 7644), S. aureus (ATCC 33862) and C. sakazakii (ATCC 51329) were 203 
used for the inoculation studies. Working stocks of L. monocytogenes, S. aureus, and C. sakazakii  204 
were kept at  −20 °C in Brain Heart Infusion nutrient broth (Oxoid Limited, Basingstoke, UK). 205 
Nutrient broth was added with 20% glycerol as cryogenic protective agent. Fresh cultures were 206 
prepared in their early stationary growth phase for each experiment by inoculating a loop of the 207 
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frozen culture in 9 mL of the respective sterile culture medium and then incubating the cultures at 208 
37 °C for 24 h. The microbial counts were monitored by measuring the optical density at 600 nm 209 
and confirmed using a culture-based method. The resulting L.monocytogenes, S. aureus and C. 210 
sakazakii cell suspensions contained about 10
9
 colon forming units (CFU)/mL (OD 0.90 ± 0.03). 211 
The culture-based method involved spreading 0.1 mL of the appropriate serial dilutions in peptone 212 
water (Merck) onto specific appropriate media, incubated at 37 °C, and the colonies were counted 213 
after 24 h: final concentration of 1.5 x 10
9
 CFU/mL for L. monocytogenes, 3x10
9
 CFU/mL for S. 214 
aureus and 1.6 x 10
9
 CFU/mL for C. sakazakii were confirmed by means of plate counts on 215 
appropriate selective media. 216 
2.4.3 SHM inoculum.  217 
L. monocytogenes, S. aureus and C. sakazakii were inoculated in 500 mL of SHM in sterile Pyrex 218 
bottles (see Table 1 for the inoculum loads). Each pathogen was inoculated in a single batch. 219 
Inoculated samples (IHM) were kept refrigerated until they were pasteurized, for a maximum of 30 220 
min. 221 
2.4.4 HTST pasteurization of IHM and cleaning of the system. 222 
IHM samples of each pathogen were HTST pasteurized (PHM) and collected in sterile Pyrex 223 
bottles. The samples were kept refrigerated for about 20 h before the microbiological analyses. 224 
After each pasteurization cycle, the HTST equipment was cleaned by pumping 3% v/v Divoflow 225 
(JohnsonDiversey S.p.A., Milan, Italy) detergent solution at 50 °C (1 L) through the system in the 226 
CIP (cleaning-in-place) mode for 10 min, and this was followed by tap water for 5 min. The day 227 
after each experiment, rinsing water (500 mL) was allowed to recirculate in the system for 10 228 
minutes, collected in a sterile Pyrex bottle and checked for pathogenic growth. 229 
2.4.5 Microbiological analyses of the HTST pasteurized IHM.  230 
Colony counts of PHM were performed in triplicate. As the absence of pathogen growth is required 231 
after pasteurization in HMB, undiluted samples were also subjected to microbiological screening. 232 
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The presence of S. aureus was determined using the method described in 2.4.1. L. monocytogenes 233 
was evaluated by enriching with Demi-Fraser and Fraser (Sifin, Berlin, Germany) media incubated 234 
at 37 ºC for 24 h (EN/ISO 11290, 1996); a subsequent growth on OCLA and PALCAM agar 235 
mediums (Oxoid) was allowed for both enriching media at 37 ºC for 48 h. C. sakazakii was 236 
determined by measuring the growth on the Enterobacter sakazakii Isolation Agar (ESIA) ready-237 
made plates (Liofilchem s.r.l. Roseto degli Abruzzi (Te), Italy) (AFNOR V08-054).  238 
 239 
2.5 Experiment 2: Evaluation of the biochemical profile of HTST and Holder pasteurized 240 
milk. 241 
The RHM, HTST-HM and HoP - HM from trays 1 and 2 of the HMB Holder pasteurizer were 242 
assayed to establish the sIgAs content, BSSL and lysozyme activity, as well as the protein profile. 243 
The sIgAs were assayed on 1:10,000 diluted samples, using an ELISA kit (Biovendor, Kassel, 244 
germany) following manufacturer's instructions, in triplicate. BSSL activity was measured in 245 
triplicate according to a previously described protocol (Bertino et al., 2013), with minor 246 
modifications. Briefly, an aliquot of 2 mL of substrate solution (25 M Tris-HCl pH 9.0, 0.25 mM 2-247 
methoxyethanol, 0.53 mM p-nitrophenyl myristate in DMSO, 5 mM sodium cholate) was added to 248 
50 µL of undiluted (for all pasteurized samples) or diluted (1:1000 for RHM) milk samples, mixed 249 
and left to incubate at room temperature for 60 min. Then, 1 mL of stop solution (acetone/n-heptane 250 
5:2 vol/vol) was added, and immediately mixed by inversion. After centrifugation for 15 min at 251 
6500rpm at 4 °C, absorbance of the lower aqueous phase was measured at 405 nm. Lysozyme 252 
activity was tested in triplicate on 1:200 diluted samples using a fluorescence-based kit (EnzChek 253 
Lysozyme Assay Kit, Thermo Fisher Scientific, Waltham, USA) following to the manufacturer's 254 
instructions. The assay measures lysozyme activity as the increase in fluorescence resulting from 255 
the enzyme activity on Micrococcus lysodeikticus cell walls labeled with fluorescein . Active 256 
lysozyme enzyme hydrolyzes the b-(1-4)-glucosidic linkages between the N-acetylmuramic acid 257 
and N-acetyl-D-glucosamine residues in the mucopolysaccharide cell wall, relieving the quenching 258 
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and yielding an increase in fluorescence that is proportional to lysozyme activity. The total protein 259 
content was determined in triplicate on HM samples, skimmed by means of centrifugation at 2000g 260 
at 4 °C for 30 min, using a 2DQuant kit (GE Healthcare Europe, Milan, Italy), following the 261 
manufacturer’s instructions. The protein profile (in reducing and non reducing conditions, 5 µg of 262 
proteins) was visualized by mono dimensional electrophoresis on a 10-well 12% Nu-PAGE® 263 
precast gel, with MES as the running buffer, on a Novex Mini-cell (Thermo Fisher Scientific) at 264 
200 V. The gels were stained with Blue Coomassie Colloidal stain, according to the protocol 265 
already described in a previous study (Giribaldi et al., 2013). 266 
 267 
2.6 Statistical analyses 268 
Data on the performed biochemical analyses were analysed using the KyPlot 2.0 statistical software 269 
(Kyens Lab Inc., Tokyo, Japan), with one-way ANOVA at a significance of below 0.05 to assess 270 
significant differences. When the calculated values of F were significant, Tukey’s post-hoc analysis 271 
was used to classify any significant difference between the mean values. 272 
 273 
3. RESULTS  274 
3.1 Setting up the pasteurization parameters. 275 
The instrument was preliminarily tested on bovine milk in order to assess its suitability for 276 
performing a proper HTST pasteurization cycle, and the test was successful. The new HTST system 277 
correctly performed a pasteurization cycle (72 °C for 15 s), since the marker enzyme, that is, 278 
alkaline phosphatase, resulted to be inactivated in a pasteurized bovine milk sample. A shorter 279 
retention time (10 s) was also tested, and was found not to be sufficient to inactivate the alkaline 280 
phosphatase in the bovine milk. By setting the pasteurization conditions at 72 °C for 15 s, the 281 
lactoperoxidase activity was preserved in a pasteurized bovine milk sample, thus meeting the 282 
requirements for the HTST pasteurization of bovine milk. 283 
 284 
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3.2 Microbiological and challenge tests on HTST pasteurized HM. 285 
In order to assess the natural contamination of the starting donated milk pool (OHM) from the 286 
HMB, its background microflora was analysed. The total viable bacteria count (TVC), coagulase 287 
positive Stafilococci and Enterobacteriaceae loads are reported in Table 2. No L. monocytogenes or 288 
C. sakazakii were found.  289 
After prolonged pasteurization by means of HoP, the absence of vegetative forms of 290 
microorganisms was assessed, and the resulting milk was considered “sterile” (SHM). This milk 291 
was used as the starting material for the challenge tests. The milk was inoculated (IHM) with L. 292 
monocytogenes, S. aureus and C. sakazakii in order to perform the challenge tests; the bacterial 293 
counts of the starting inocula are reported in Table 1. PHM did not show any pathogen growth after 294 
the HTST pasteurization conducted with the new prototype, in any of the performed challenge tests, 295 
as assessed by both qualitative and quantitative methods. At the same time, the rinsing water did not 296 
present any growth of the inoculated microorganism. The efficiency of both the Holder and HTST 297 
pasteurization was also tested in Experiment 2 (see Figure1B for the experimental design) by 298 
measuring the bacterial loads before and after the pasteurization of naturally contaminated milk 299 
(Table 1). No bacteria were detected in the milk following either pasteurization procedure. 300 
 301 
3.3 Evaluation of the biochemical profile of HTST and Holder pasteurized milk. 302 
The qualitative changes between RHM, HTST-HM and HoP-HM, as performed directly in an HMB 303 
device, were determined in Experiment 2 by measuring the sIgAs content, and BSSL and lysozyme 304 
activity, and by profiling the protein profile in both reducing and non-reducing conditions. 305 
A monodimensional denaturing protein electrophoresis was run on all the samples, in order to 306 
profile any major change induced by the different pasteurization methods on the protein pattern. 307 
The resulting images are shown in Figure 2. The protein profiles seemed to be very similar, as far as 308 
the reducing conditions are used (lanes 1-4), without any visible degradation of the specific bands 309 
following any of the pasteurization processes. Accordingly, the lysozyme activity was measured 310 
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and no significant difference was found between HTST- and HoP-HM (Tab. 3). In addition, the 311 
lysozyme activity value measured in both of the pasteurized samples did not differ significantly 312 
from the value found in RHM (50.2±0.2 U/μL). However, the protein profiles in the non-reducing 313 
conditions (lanes 6-9) displayed some differences in the high molecular weight bands following all 314 
the pasteurization processes. 315 
The sIgAs content of HTST- and HoP-HM was determined and retention rates with respect to RHM 316 
were calculated. HoP-HM was found on average to retain 46.3% sIgAs, although a noteworthy 317 
difference was observed between the two samples pasteurized in the two different trays 318 
(36.8±21.6% vs. 55.8±3.1%). HTST-HM showed a significantly higher sIgAs retention. As for the 319 
BSSL activity retention, in both HoP and HTST the enzymatic activity resulted to be almost 320 
completely destroyed with respect to RHM (145±22 μmol/mL/min); nevertheless, HTST-HM 321 
displayed a significantly higher activity than HoP-HM (Tab. 3). No significant difference in HoP-322 
HM was observed between the two trays (data not shown). 323 
 324 
4. DISCUSSION 325 
A new apparatus for the HTST pasteurization of HM has been tested in order to verify its ability to 326 
eliminate selected pathogens as well as to assess the effect of pasteurization on the milk protein 327 
profile and selected nutritional and immunological parameters. The instrument was preliminarily 328 
tested to assess its ability to perform a proper HTST pasteurization cycle on bovine milk, and some 329 
commonly used technological parameters confirmed that the test was successful (positive 330 
peroxidase and negative alkaline phosphatase reactions in the pasteurized milk). The raw human 331 
milk used for the experiment resulted to be highly contaminated by coagulase-positive 332 
Staphylococcus spp. Human milk contains commensal bacteria, and in particular non-pathogenic 333 
coagulase-negative Staphylococci from the bacterial flora of the maternal skin. The transmission of 334 
pathogens, such as Staphylococcus aureus, has also been reported (Heikkila & Saris, 2003). The 335 
starting raw milk pools delivered from the bank showed a similar background microflora to that 336 
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already observed in a previous experiment by our group on HM from a Neonatal Intensive Care 337 
Unit (Giribaldi et al., 2013).  338 
The milk was completely pasteurized by prolonged Holder treatment, thus constituting SHM for 339 
inoculation. The inocula for the challenge tests (L. monocytogenes, S. aureus and C. sakazakii) were 340 
chosen on the grounds of being high-risk pathogens that cause the contamination of milk and 341 
neonatal infections. All the pathogens were eliminated by the HTST pasteurization performed with 342 
the new instrument. When HoP and HTST were used to eradicate the natural background microflora 343 
of the HM in the present study, no bacterial growth was observed, even in the presence of high 344 
microbial loads, including Enterobactericeae. These results are in agreement with the first reports 345 
that measured the efficacy of HTST on naturally contaminated HM: Goldblum et al. (1984) found 346 
complete pasteurization of HM after HTST by using a plate-type industrial heat exchanger and 347 
injecting HM in a sterile water stream. Challenge tests by Dhar et al. (1996) and by Terpstra et al. 348 
(2007) confirmed the efficacy of small-scale laboratory devices, based on continuous flow HTST 349 
pasteurization, on inoculated Escherichia coli, S. aureus and Streptococcus agalactiae. Terpstra et 350 
al. (2007) also investigated the efficacy of HTST on HM samples inoculated with 3 lipid-enveloped 351 
and 2 non-enveloped viruses. The system was shown to be highly effective against lipid-enveloped 352 
viruses (HIV and marker viruses for hepatitis B and C). The efficacy of a low cost simulated HTST 353 
to be used in resource-limited settings (FoneAstra system) has also been reported. The FoneAstra 354 
system resulted to be a reliable, low-cost pasteurization monitoring and reporting systems to be 355 
used worldwide for treating donor milk (Naicker et al., 2015) 356 
The biochemical parameters used to assess the quality of pasteurized milk were selected from 357 
among the most commonly measured in previous studies on the effect of HoP on HM. Attention 358 
was focused in particular on parameters that are significant from an immunological and/or 359 
nutritional point-of-view, and which had previously been reported to be decreased by HoP 360 
pasteurization (Tully et al., 2001). Both sIgAs and BSSL resulted to be significantly higher in the 361 
milk pasteurized with the new HTST pasteurizer than in the milk treated with the standard HoP, 362 
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conducted according to the HMBs guidelines and using an HMB pasteurizer. sIgAs represents the 363 
majority of IgA in HM (Goldsmith et al., 1983). In early reports, the retention of sIgAs and /or the 364 
total IgAs following HTST was found to be complete (Goldblum et al., 1984), decreased with 365 
respect to raw milk (about 60% for Dhar et al., 1996) and equal to that of HoP with respect to raw 366 
milk (63% according to Goldsmith et al., 1983; 80% for Hamprecht et al., 2004; 40% for Mayayo et 367 
al., 2016). In the present experiment, the amount of HTST-retained IgAs following the treatment of 368 
the milk with the new apparatus was almost twice as high as the IgAs content of the same milk 369 
processed with HoP (as measured in a real HMB implemented pasteurizer), and higher than the 370 
levels reported in previous investigations. However, the results concerning the IgAs content 371 
following the two pasteurization systems need to be confirmed on a larger number of samples, since 372 
it is well documented that the range of variation of IgAs values as affected by Holder pasteurization 373 
is very high (Peila et al., submitted).As for lysozyme activity, no significant difference was found in 374 
the present study in either of pasteurized samples,  compared to raw milk. This result is in contrast 375 
with previous findings, which reported a decrease in lysozyme as an effect of HoP (Sousa, Santos, 376 
Fidalgo, Delgadillo, & Saraiva, 2014; Viazis, Farkas, & Allen, 2007), as well as of HTST 377 
pasteurization (Mayayo et al., 2016). In all these reports, lysozyme activity was determined using a 378 
Micrococcus lysodeikticus-based turbidimetric assay, which measures to what extent bacterial 379 
growth is prevented by the addition of lysozyme-containing samples. However, HM is a complex 380 
mixture of several anti-bacterial factors, whose degradation may also have an impact on the lower 381 
rates of the measured “lysozyme activity”, when it is measured as previously described. In the 382 
present study, an attempt was made to overcome this problem using an assay in which the specific 383 
lysozyme muramidase activity is measured by quantifying the fluorescence released from labeled 384 
M. lysodeikticus cell walls. This difference in the analytical approach can explain the discordance 385 
from literature and points out the need for appropriate analytical tools and a correct interpretation of 386 
the results. 387 
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Following both types of pasteurization, BSSL displayed an activity almost 1,000-fold lower in 388 
comparison to the activity recorded in the RHM sample. The almost complete disruption of lipase 389 
activity following any pasteurization treatment, confirms previous reports (Goldblum et al., 1984; 390 
Hamprecht et al. 2004), although the measured activity in those investigations was not exclusively 391 
due to BSSL. The lipase activity in the present study has been much lower than that observed in a 392 
previous study by our group (Baro et al., 2011). Again in that case, lipase activity was measured 393 
without the induction of bile salts. Nevertheless, the BSSL bioactivity resulted to be significantly 394 
higher in the HTST treated samples than in the HoP samples.  395 
As far as the protein profile modification in pasteurized HM is concerned, no qualitative difference 396 
was found between RHM, HoP and HTST in the reducing conditions. This result is in contrast with 397 
previous findings of our group (Baro et al., 2011) and of Mayayo et al. (2014) for HoP, which were 398 
obtained in non-reducing electrophoretic conditions. Conformational differences, if any, may be 399 
detected more easily when non-reducing electrophoresis is used. This is confirmed by the fact that 400 
Mayayo et al. (2014) were not able to profile any change in the protein pattern following HoP when 401 
reducing conditions were used. Therefore, a non-reducing electrophoresis was run, and some slight 402 
degree of polymerization for high molecular weight protein bands was observed (probably 403 
ascribable to lactoferrin and immunoglobulins), thus confirming the results of Baro et al. (2011) and 404 
Mayayo et al. (2014). In conclusion, the new bench-top HTST apparatus can effectively pasteurize 405 
HM with a better retention of the sIgas content and BBSL activity, compared to standard Holder 406 
pasteurization. 407 
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TABLE 1. Challenge tests: effect of HTST pasteurization on human milk.  503 
Inoculated pathogens Initial loads in 
IHM
1 
(CFU/mL) 
Final loads in PHM
1 
(CFU/mL) 
   
Listeria monocytogenes  1.2 x 10
6
 absent in 25 ml 
Staphylococcus aureus 3.0 x 10
6
 < 100 
Chronobacter sakazakii 1.6 x 10
6
 absent in 10 ml 
1
 IHM = inoculated human milk; PHM = HTST pasteurized milk. 504 
 505 
TABLE 2. Background microflora of human milk (starting Pools 1 and 2)  506 
 Pool 1 (OHM)
1 
(CFU/mL) Pool 2 (RHM)
1 
(CFU/mL) 
   
Total viable count  1.0 x 10
6
 7.7 x 10
4 
Coagulase-positive Staphylococci 2.5 x 10
5
 1.1 x 10
4 
Enterobacteriaceae < 10 2.1 x 10
2 
1
 OHM = original human milk for Experiment 1; RHM = raw human milk for Experiment 2 507 
 508 
TABLE 3. Nutritional milk characteristics as affected by Holder and HTST pasteurization.  509 
Parameter (Unit) HoP-HM
1
 HTST-HM
1 
   
sIGAs (% of RHM
1
) 46.3±13.2
a
 78.9±2.4
b 
BSSL activity (μmol/min/mL) 0.09±0.03a 0.26±0.10b 
Lysozyme activity (U/μL) 52.3±3.2 48.8±0.8 
1 
HoP-HM = Holder pasteurized milk; HTST-HM = HTST pasteurized milk; RHM = raw milk
 510 
23 
 
a 
The data represent  the standard deviations of the means obtained from  three independent replicate 511 
experiments. Different superscript letters indicate significant Tukey's post-hoc mean differences 512 
across each row. 513 
 514 
  515 
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Figure Captions 516 
 517 
FIGURE 1. Experimental design and workflow for Experiment 1 (Panel A) and Experiment 2 518 
(Panel B). 519 
 520 
 521 
 522 
FIGURE 2. NuPAGE protein profile of the HM samples treated with the different pasteurization 523 
processes. Lanes 1 to 4, samples run in reducing conditions: 1) RHM = raw milk; 2) HoP-HM = 524 
Holder pasteurized milk Tray 1; 3) HoP-HM = Holder pasteurized milk Tray 2; 4) HTST-HM = 525 
HTST pasteurized milk; 5) Molecular weight standards. Lanes 6 to 9, samples run in non-reducing 526 
conditions: 6) RHM = raw milk; 7) HoP-HM = Holder pasteurized milk Tray 1; 8) HoP-HM = 527 
Holder pasteurized milk Tray 2; 9) HTST-HM = HTST pasteurized milk. Colloidal Coomassie Blue 528 
stain.  529 
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